跳至主要内容
临床试验/NCT01283503
NCT01283503已完成1 期

A Phase I Study of BKM120, Administered Orally in Adult Japanese Patients With Advanced Solid Tumors

Novartis Pharmaceuticals1 个研究点 分布在 1 个国家目标入组 15 人开始时间: 2009年10月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
1 期
状态
已完成
入组人数
15
试验地点
1
主要终点
establish Maximum tolerate dose (MTD)

研究概览

简要总结

In this study, BKM120 will be administered to adult patients with advanced solid tumors whose disease has progressed despite standard therapy or for whom no standard therapy exists. The trial will confirm the safety and tolerability and determine the maximum tolerated dose (MTD) of BKM120 in Japanese patients.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
20 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patients with histologically confirmed, advanced unresectable solid tumors who have progressed on (or not been able to tolerate) standard therapy or for whom no standard anticancer therapy exists.
  • At least one measurable or non-measurable lesion as defined by RECIST guidelines for solid tumors.
  • Age ≥ 20 years
  • Eastern Cooperative Oncology Group Performance Status (ECOG P.S.) of ≤ 2
  • Life expectancy of ≥ 12 weeks
  • Patients must have the laboratory values

排除标准

  • Patients with a history of primary central nervous system tumors or brain metastases or who have signs/symptoms attribute to brain metastases and have not been assessed with radiologic imaging to rule out the presence of brain metastases
  • Prior treatment with a PI3K inhibitor
  • Patients with any peripheral neuropathy ≥ CTCAE grade 2
  • Patients with unresolved diarrhea ≥ CTCAE grade 2
  • Women of child-bearing potential who are pregnant or breast feeding. Men or women of reproductive potential not to sign informed consent for birth control. Barrier contraceptives must be used throughout the trial and six months after the end of treatment.
  • Other protocol-defined inclusion/exclusion criteria may apply

研究组 & 干预措施

BKM120

Experimental

干预措施: BKM120 (Drug)

结局指标

主要结局

establish Maximum tolerate dose (MTD)

时间窗: every day up to first 4 weeks

次要结局

  • Efficacy assessed by RECIST(Every 2 months)
  • Establishment of a pharmacokinetic profile by collecting information on parameters including but not limited to Cmax, Tmax, T1/2 and AUC in plasma samples(Every 2 weeks up to first 4 weeks, then every odd cycle)
  • Measurement of biomarkers for PI3K pathway in blood and tissue(First 4 weeks)
  • Safety assessed by type, frequency and severity of adverse events(Every week)

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验